Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Figure 1 Graphical representation of overall survival in patients diagnosed with neuroendocrine tumors treated with peptide receptor radionuclide therapy. A median survival of 12.5 mo is shown (95% confidence interval: 9.8–15.2).

Figure 2 Representation of cumulative survival in the population studied according to the histological tumor grade. Grade 1 (blue), grade 2 (green) and grade 3 (gray) demonstrating that overall survival is inversely proportional to tumor grade.

Figure 3 Representation of cumulative survival in patients treated with primary tumor surgery and metastases with peptide receptor radionuclide therapy (green) and patients treated only with peptide receptor radionuclide therapy (blue). A: For patients treated with primary tumor surgery, the probability of long-term survival is higher when treated with peptide receptor radionuclide therapy, showing the existence of a directly proportional relationship between survival and surgical treatment; B: The patients treated with metastases.

Figure 4 Representation of cumulative survival in patients with (green) and without (blue) bone metastasis. The probability of long-term survival is higher in the second group.